BB Biotech AG (BION.SW) - Deep Dive Research Report

Prepared: 2026-05-25

1. What the company does

BB Biotech AG is a Swiss-listed investment company that does one thing: it owns shares in publicly traded biotech drug developers. It is not a drug company. It does not run trials, file INDs, or operate labs. It is a permanent-capital vehicle that gives shareholders a single, liquid security through which they get exposure to a curated basket of 20-50 biotechnology equities, mostly small-and-mid-cap US names with deep clinical pipelines, alongside a smaller tail of large-caps like Vertex, Gilead, and Regeneron.

The company was incorporated as an Aktiengesellschaft in Schaffhausen on November 9, 1993 and listed on the SIX Swiss Exchange on December 27, 1993. It added Frankfurt in December 1997 and traded on Milan's Nuovo Mercato from 2000 until delisting there in September 2023. Operations are handled by Bellevue Asset Management AG, a Zurich-based investment manager owned by Bellevue Group (whose largest shareholder is founder Martin Bisang). BB Biotech itself has no employees - the "company" is a board of directors, an investment management mandate with Bellevue, and a balance sheet of biotech equities. (Wikipedia)

The structure matters. BB Biotech is a closed-end fund, which means its share count is fixed (subject to buybacks or issuance). Unlike an open-ended mutual fund, redemptions cannot force the manager to sell positions at the wrong time. This lets Bellevue hold illiquid mid-caps through volatility windows in a sector that routinely sees individual names move 30-50% on a single Phase III readout. The cost is that the share price disconnects from net asset value: BION traded at a 10.8% discount to NAV at year-end 2025 and a 6.9% discount at March 31, 2026, with the discount oscillating between premiums and 15%+ discounts over the cycle.

The value proposition is therefore three-layered:

1. Concentrated stock picking in a sector that is intellectually expensive to underwrite. The Bellevue team has medical and PhD-level scientific backgrounds (head Christian Koch holds a PhD in Computer-Assisted Drug Design from ETH Zurich) that retail investors cannot replicate by reading press releases.
2. A 5% annual dividend computed mechanically as 5% of the average December share price, paid each March, in a sector that almost never pays dividends. This converts capital-gain volatility into a predictable income stream.
3. A NAV-linked discount/premium dynamic that itself can be a return source for patient buyers when discounts widen and a return drag when premiums collapse.

The Bellevue team's stated philosophy: invest in companies with differentiated science targeting diseases of high unmet medical need, hold them through the value-inflection points (data readouts, approvals, M&A), and recycle proceeds from buyouts back into the next pipeline of mid-caps. Q1 2026 alone saw Terns Pharmaceuticals (a new position initiated in Q1) acquired by Merck before quarter-end. In 2025, five portfolio companies were acquired: Akero by Novo Nordisk (announced Oct 2025, closed Dec 2025, ~$4.7bn), Blueprint Medicines by Sanofi ($9.5bn, announced June 2025), Amicus Therapeutics by BioMarin, Avidity Biosciences (shortly after BB Biotech initiated the position in September), and others. M&A is not a side-effect of the strategy; it is the strategy.

2. Business segments

BB Biotech is a single-segment business. Its only activity is holding equity positions in biotechnology companies. There is no operating segmentation by therapeutic area, geography, or vehicle type in the financial statements. Section 2 therefore does not apply.

The closest thing to a segment-level view is the therapeutic-area allocation, which the company discloses but does not present as separate reportable segments: orphan diseases, immunology, oncology, neurological diseases, and cardiometabolic medicine. These are covered in Section 3.

3. Products and business detail

There is one "product": a share of BB Biotech AG. Behind that share sits a portfolio of biotech equities. The interesting business detail is not the share class structure - it is the composition and management of the portfolio itself.

Portfolio construction rules

Until early 2026, the investment guidelines required a portfolio of 20-35 listed biotech holdings. At the Q1 2026 report (April 24, 2026), this band was widened to 20-50 positions. Management has explicitly framed this as an expansion of the opportunity set, enabled by an enlarged investment team and the integration of AI-assisted screening tools. Concentration rules survived the widening: 5-8 core positions account for roughly two-thirds of the portfolio, and no single position can exceed 25% of NAV. At least 90% of the portfolio must be in listed names; the remainder may be held in private positions through BB Biotech Ventures, a separate but related vehicle.

Top holdings and therapeutic mix (as at March 31, 2026)

Source: BB Biotech portfolio overview

Geography and structure

Holdings are overwhelmingly US-listed (Nasdaq); European listings such as Argenx and Immunocore round it out. There is no Asian biotech exposure of note. This US tilt matters because most of BB Biotech's NAV swings are USD-denominated; in Q2 2025 the company explicitly flagged a USD/CHF depreciation of 10.2% as "the main drag" on CHF-denominated NAV. The share is priced in CHF on SIX (BION.SW) and in EUR on Frankfurt (BBZA).

Investment manager and analytical process

Bellevue Asset Management AG runs the portfolio under a long-standing investment management mandate. Christian Koch took over as head of the BB Biotech team on January 1, 2025, after eleven years at Bellevue, succeeding the previous leadership during a transition period. The team has progressively integrated AI-enabled analytical tools into its process. Management referenced these as "agentic-AI tools" in the Q2 2025 release and labelled the proprietary platform "BioCarta" in February 2026 commentary. The technical edge claim is that machine-assisted screening of trial data, competitor pipelines, and publication patterns surfaces opportunities the team's human analysts then validate. (finews report on FY2025 slides)

Capital actions

Two mechanisms move capital between BB Biotech and shareholders:

• Annual dividend equal to roughly 5% of the volume-weighted average December share price, paid in March each year, in place since 2013.
• Share buybacks, executed through second-trading-line programs on SIX with the explicit intent of cancelling the bought-back shares (capital reduction). A 2022 program ran from April 13, 2022 to April 11, 2025 and retired 250,750 shares. A new program covering up to 10% of share capital was launched in 2025 for a three-year window. (BB Biotech share buyback page)

4. Customers

The customer is the shareholder, and the buying decision is "do I want pre-curated exposure to clinical-stage biotech without the time or expertise to do the picking myself, and am I willing to pay the management fee and accept a discount-to-NAV in return?"

There are three identifiable customer types:

Swiss and German retail income investors. The 5% dividend yield, paid annually in CHF in March, is unusual in biotech. For a Swiss retiree or income-focused private investor, BION delivers something no biotech ETF (XBI, IBB) and almost no individual biotech stock delivers: a high single-digit yield tied to a high-volatility sector. The 2026 inclusion in the SPI Select Dividend 20 Index (effective March 23, 2026) cemented this profile. (Q1 2026 release)

European investors who want biotech exposure but cannot or do not want to hold US securities directly. Many European private banks and pension wrappers find direct US small-cap biotech awkward (custody, tax, settlement, currency operations). BION is a clean Swiss-listed line item that delivers similar economic exposure.

Discount arbitrageurs and closed-end fund specialists. A subset of buyers explicitly trade the NAV discount. They buy when the discount widens past historical norms (saw 15%+ at year-end 2024) and trim when it narrows. The board's persistent capital management - buybacks specifically aimed at the discount - is calibrated to this audience.

There is no concentration risk in the traditional sense; the shareholder base is fragmented. Bellevue Group is itself not a meaningful direct owner of BB Biotech shares; its economic interest is through the management fee.

Switching cost is low. A holder can sell BION and buy XBI tomorrow. What the company sells is a track record, an income stream, and a thesis (active stock picking in a sector where indexing is suboptimal because the median small-cap biotech is a value destroyer). The retention bet is therefore performance plus dividend reliability. The 2025 dividend cut from CHF 2.00 to CHF 1.80 (driven by a lower December 2024 share price) is the kind of event that tests this loyalty.

5. Competitive landscape

The competitive set splits into three groups, all of which offer biotech exposure but with very different cost, structure, and active-management profiles.

Passive biotech ETFs (XBI, IBB). SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) are the elephants in the room. They charge ~35-45 bps versus a higher implied fee on BB Biotech, they trade at NAV without discount risk, and they offer instant diversification. Where BB Biotech wins: the team can avoid the long tail of clinical-stage names that destroy capital (the "Wild West" of small-cap biotech, where well over half of phase II readouts fail). Where it loses: in a roaring bull market for biotech (the 2020-2021 SPAC frenzy), index exposure beats concentrated active picking because every junk biotech rallies and BB Biotech's quality screen leaves money on the table.

US closed-end biotech funds (HQH/HQL Tekla Healthcare, others). Tekla Healthcare Investors (HQH) and Tekla Life Sciences Investors (HQL) are structurally the closest analogues - US closed-end funds focused on biotech with quarterly distributions. They also routinely trade at discounts. The pitch for BB Biotech versus these vehicles is European-listed, CHF-denominated, an established 30+ year track record, and a more concentrated portfolio. The pitch against is that Tekla funds offer monthly/quarterly distributions and have stronger US investor familiarity.

Direct stock picking. For a sophisticated investor, the alternative to BION is just buying Vertex, Argenx, and Regeneron directly. This skips the management fee and the discount risk. Where BB Biotech defends: the small-cap part of the portfolio (Scholar Rock, Viridian, Krystal, Crinetics) requires the kind of due diligence that retail and even most generalist institutional investors cannot perform credibly.

Barriers to entry are low in theory - anyone can launch a biotech fund - but high in practice. The barrier is not legal or capital; it is reputation and platform. Bellevue has 30+ years of cumulative pattern recognition on drug-development risk, named scientific advisors, and a track record investors can underwrite. A new entrant can match the structure overnight; matching the credibility takes a cycle.

The structural shift to watch in 2026 is AI integration. If BioCarta or similar platforms genuinely produce sustained alpha, they could compress the differentiation that justifies an active management premium - or they could entrench it for firms that build them first. BB Biotech's claim to be early on this is real but unverified by externally audited performance attribution.

6. Industry

The relevant industry is publicly traded biotechnology equities globally, with a heavy weighting to the US Nasdaq biotech ecosystem (the Nasdaq Biotechnology Index has roughly 250-270 constituents). Three structural forces drive demand for what BB Biotech sells.

The patent cliff is the dominant tailwind through 2030. Approximately $200+ billion in big-pharma revenue faces loss-of-exclusivity through the latter half of the 2020s as drugs like Keytruda, Eliquis, Ozempic-class GLP-1s, and others lose patent protection. Big pharma's response is M&A. BB Biotech's Q3 2025 release explicitly cited this dynamic: "a historic patent cliff is driving renewed M&A and partnership activity as large pharmaceutical companies seek to replenish pipelines with innovative assets." This is the single most important industry-level demand driver for the assets BB Biotech holds. The 2025 take-out tally - five portfolio companies acquired in one year - is the direct evidence.

Macro liquidity drives the multiple. Biotech is a long-duration asset class; the cash flows from a Phase II drug today might arrive in 2030+. The sector is therefore acutely sensitive to interest rates. The 2022-2024 rate-hike cycle compressed valuations across XBI by 50%+ from peak. The first US Federal Reserve rate cut of 2025 was specifically called out by management in the Q3 2025 release as "supporting risk appetite and improved financing conditions." A further easing cycle through 2026-2027 is a meaningful tailwind for the asset class; a re-acceleration of inflation forcing rates higher would be a meaningful drag.

Innovation cycles drive the long-term return. The big platform shifts of the last decade - GLP-1s for metabolic disease, mRNA, antisense oligonucleotides, RNAi, gene therapy, ADCs, CAR-T - have all created multi-billion-dollar opportunities. BB Biotech's portfolio is explicitly oriented around the next wave of these: RAS-targeted oncology (Revolution Medicines), topical gene therapy (Krystal), Fc-blocking antibodies (Argenx), FGF21 analogues for MASH (Akero, acquired by Novo Nordisk), and so on.

The regulatory environment matters more than ever. The 2026 outlook released with the Q1 2026 report flagged "elevated trade policy uncertainty" and "healthcare policy and regulatory uncertainty in the US" as overhangs. The Trump administration's Most Favored Nation drug pricing executive orders, tariff regimes affecting pharma supply chains, and FDA leadership turnover all introduce a layer of regulatory volatility that did not exist five years ago. This is a sector-wide headwind that BB Biotech cannot diversify away.

Cyclicality. Biotech is one of the more cyclical equity sectors despite the underlying secular demand for new medicines, because financing conditions for clinical-stage companies (who burn cash for years) are themselves cyclical. BB Biotech's NAV moves materially with sector-wide sentiment as much as with company-specific milestones - this is visible in the Q1 2025 result (CHF 241m loss) vs Q3 2025 (CHF 448m profit) just two quarters apart.

7. Growth triggers

All triggers below are sourced directly from the four most recent quarterly releases. BB Biotech does not hold traditional "concalls" in the sell-side sense; the releases and supporting investor presentations are the equivalent disclosure.

• Apitegromab approval and launch for SMA (Scholar Rock). Identified as one of four anticipated H2 2025 product launches in the Q2 2025 release (July 25, 2025). Scholar Rock is a top-10 holding at 6.2% weight; commercial uptake of apitegromab is a direct NAV driver.

• Donidalorsen launch (Ionis). Also identified in the Q2 2025 release as an H2 2025 launch.

  "Four anticipated product launches: Apitegromab (Scholar Rock), Donidalorsen (Ionis), Mitapivat (Agios), and Troriluzole (Biohaven)." (Q2 2025 release, July 25, 2025)

• Revolution Medicines daraxonrasib Phase III in pancreatic cancer. Repeatedly flagged across the FY 2025 (Feb 20, 2026) and Q1 2026 (April 24, 2026) releases as one of the highest-conviction 2026 catalysts. Revolution Medicines is a top-10 holding at 5.2% weight.

• Argenx Vyvgart franchise Phase III readouts. Multiple readouts expected across 2026 expanding the indication base for efgartigimod beyond myasthenia gravis. Cited in the FY 2025 outlook. Argenx is the #2 holding at 8.0% weight.

• Viridian Therapeutics Phase III data in thyroid eye disease. Identified as a 2026 catalyst in the FY 2025 release. Viridian is a top-10 holding at 4.6% weight, increased through 2025.

• Alnylam Amvuttra commercial rollout. Flagged in the FY 2025 release as a 2026 commercial inflection point following label expansion. Recurring trigger across multiple releases.

• Krystal Biotech and Wave Life Sciences rare-disease pipelines. Identified as 2026 catalysts in the FY 2025 release within the rare-disease vertical.

• Continued M&A take-outs in the portfolio. A standing trigger explicitly tied to the patent cliff thesis. Five 2025 take-outs (Akero, Blueprint, Amicus, Avidity, plus one) already evidenced; Terns acquisition by Merck in Q1 2026 continued the pattern.

  "Terns Pharmaceuticals, a new Q1 investment, was acquired by Merck on March 25, 2026, confirming continued strategic M&A demand for innovative biotech assets." (Q1 2026 release, April 24, 2026)

• Discount-to-NAV compression through buybacks. The new 10% three-year buyback program launched in 2025 provides a mechanical lever to narrow the discount when it widens. The Q1 2026 discount narrowing from 10.8% to 6.9% reflects this dynamic.

• AI-enabled investment process scaling (BioCarta platform). Management has flagged the integration of agentic-AI tools as enabling the expansion from 20-35 to 20-50 positions, which in turn supports a broader pipeline of M&A take-out candidates. (Q1 2026 release, April 24, 2026)

8. Key risks

Discount widening risk. This is the single biggest BION-specific risk. The share price can underperform NAV substantially for extended periods. The discount stood at 15.2% at year-end 2024, narrowed to 10.8% at year-end 2025, and to 6.9% at March 31, 2026. If sentiment turns against closed-end vehicles broadly (rising rates, redemption pressure on European retail investors), the discount can widen to 15-20%+ regardless of how the underlying portfolio performs. Buybacks help but cannot fully neutralize this risk because the buyback program is capped at 10% of capital over three years.

Currency translation risk. BB Biotech reports in CHF, dividends are paid in CHF, but ~85%+ of the underlying portfolio is USD-denominated. Q2 2025 was the textbook example: NAV declined 5.1% in CHF despite gaining 5.8% in USD, purely on a 10.2% USD/CHF move. For a CHF-investing pensioner, this is real economic loss, not an accounting artifact.

"USD vs. CHF -10.2%" currency depreciation was "the main drag" on CHF-denominated returns. (Q2 2025 release, July 25, 2025)

Concentration in single-asset binary outcomes. With 5-8 core positions accounting for ~two-thirds of NAV, the failure of a single Phase III trial in a top holding can wipe several percentage points off NAV in a day. Vertex, Argenx, Regeneron at the top reduce this somewhat (they are diversified large-caps), but mid-cap positions like Scholar Rock and Revolution Medicines carry real binary risk on individual readouts.

Manager succession execution risk. Christian Koch became head of the investment team on January 1, 2025. The strategy has been stable, but in active management, leadership transitions are real risks. The expansion from 20-35 to 20-50 positions, the introduction of AI tools, and the addition of large-cap names like Gilead and Amgen are all process changes occurring within Koch's first 16 months. If the new approach underperforms the old, attribution will be unambiguous.

Dividend cut signaling risk. The 5%-of-December-share-price dividend formula is mechanically pro-cyclical: when the share price falls, the dividend falls. The CHF 2.00 → 1.80 cut for the 2025 dividend (paid March 2026... actually the 1.80 was paid March 2025 for FY 2024) caused negative coverage in Swiss financial media. The dividend cut is structural, not discretionary, but the income-investor base may not appreciate the distinction.

Regulatory and trade-policy overhang. The Q1 2026 release explicitly flagged "macroeconomic complexity with elevated trade policy uncertainty" as a 2026 risk. US healthcare policy under the current administration - Most Favored Nation drug pricing, potential tariffs on biopharma imports, FDA approval timelines - is more uncertain than at any point in BB Biotech's recent history. This is sector-wide but bites particularly hard at clinical-stage companies who need predictable approval and pricing pathways.

Sector financing-cycle risk. Many of BB Biotech's mid-cap holdings need to raise capital to fund pivotal trials. In a financing freeze (2022 was the most recent example), even good companies dilute heavily or get acquired at distressed multiples. BB Biotech's NAV moves with this cycle.

Manager change at the board level. Dr. Clive Meanwell announced he will not stand for re-election; the board size reduces from six to five. Loss of scientific depth at the board level is a soft risk but worth noting given Bellevue's positioning.

9. Walk the talk

The four reporting periods analyzed:

• Q2 2025 release - July 25, 2025
• Q3 2025 release - October 2025
• Annual Report 2025 (Q4 + FY) - February 20, 2026
• Q1 2026 release - April 24, 2026

The most recent, Q1 2026 (April 24, 2026), is 31 days before today (2026-05-25), comfortably within the 90-day window. All four are quarterly investor releases / interim reports - BB Biotech does not run traditional sell-side earnings calls but discloses through these published releases plus accompanying investor presentations.

The Q2 2025 release laid out a specific H2 2025 launch slate: apitegromab (Scholar Rock), donidalorsen (Ionis), mitapivat (Agios), and troriluzole (Biohaven). It also flagged that the team had initiated a position in Blueprint Medicines shortly before Sanofi's $9.5bn takeover bid - a piece of validation that management was willing to highlight as evidence the process worked. They also disclosed having fully exited Esperion Therapeutics on a "weakened investment case."

"A new investment was made in Blueprint Medicines based on the strength of its lead programs - shortly before Sanofi's USD 9.5 bn takeover bid validated the company's strategic value." (Q2 2025 release, July 25, 2025)

The Q3 2025 release delivered on that thesis empirically. Net profit swung from a CHF 87 million loss in Q2 to a CHF 448 million profit in Q3. Akero Therapeutics, an existing position, received a takeover offer from Novo Nordisk (announced October 9, 2025, closed December 2025). Management used this to reinforce the M&A thesis they had been articulating since Q2:

"Novo Nordisk's announced acquisition of Akero Therapeutics" validates "continued buyer demand for differentiated science." (Q3 2025 release, October 2025)

The portfolio was sharpened to 21 positions from 23 (exited Moderna, Black Diamond, and notably Blueprint Medicines - having already locked in the Sanofi-bid gain). Management committed to "additional meaningful data readouts" in neurological, cardiovascular, and metabolic diseases over the coming quarters.

The FY 2025 / Annual Report 2025 release (February 20, 2026) delivered the full-year result: CHF 578 million net profit versus CHF 76 million in 2024, NAV up 26.5% in CHF and 44.8% in USD, beating the Nasdaq Biotech Index by 20.3 percentage points in USD. Five take-outs occurred in 2025. The dividend was proposed at CHF 2.25 (up from CHF 1.80), the buyback program was renewed for 10% over three years. The board flagged that Koch's strategic refocusing was working and explicitly named the new investments in Q4 2025 (Nuvalent, Krystal Biotech, Jade Biosciences, Maze Therapeutics, Tango Therapeutics).

The Q1 2026 release (April 24, 2026) then surprised by reversing one of those Q4 decisions: Maze Therapeutics was exited within the quarter alongside Wave Life Sciences, Amicus, Avidity (which was being acquired), and Neurocrine Biosciences. The team simultaneously initiated eleven new positions and widened the portfolio band from 20-35 to 20-50. Terns Pharmaceuticals, initiated in Q1, was acquired by Merck before quarter-end, replicating the Blueprint Medicines pattern from Q2 2025. The discount narrowed from 10.8% to 6.9%.

Promises kept:

• Q2 2025 promised H2 2025 launches; apitegromab, donidalorsen, and the others did launch in the period management indicated.
• Q3 2025 articulated the patent-cliff M&A thesis; Q4 2025 delivered Akero, Q1 2026 delivered Terns - the thesis is being externally validated.
• FY 2025 announced the new 10% buyback program; Q1 2026 reported visible discount narrowing.
• Process expansion to broader portfolio range announced in Q1 2026 was already enabled by the team-and-tools work flagged in earlier releases.

Promises adjusted quietly:

• The Q2 2025 portfolio of 23 names shrank to 21 in Q3 then to 24 by year-end and 30 by Q1 2026. The shift from "concentrated 20-35" to "broader 20-50" was a strategic pivot communicated only at Q1 2026, with the formal guideline change disclosed there. Investors who bought the original "high-conviction concentrated" pitch are now holding a fund with materially more positions and meaningful large-cap exposure (Regeneron, Gilead, Amgen) that did not exist twelve months earlier.
• Maze Therapeutics was bought in Q4 2025 and exited in Q1 2026 - a single-quarter round trip. This was disclosed cleanly but signals either a thesis change or a misjudged entry.

Promise unevenness:

• The dividend pattern through the cycle has been more volatile than messaging suggests. The "stable 5% policy since 2013" is technically correct, but the absolute CHF amount has fluctuated meaningfully (CHF 3.85 in 2022, CHF 1.80 in 2025). Management correctly describes this as policy-consistent; income-focused holders may experience it as inconsistency.

Overall assessment. Management is broadly credible and is operating in a "show, don't tell" mode. The strategic narrative (patent cliff → M&A wave → mid-cap take-outs → recycled into next pipeline) has been externally validated five times in 2025 and once already in Q1 2026. The genuine question is whether the strategic pivot to a broader, more large-cap-weighted portfolio is a reasoned evolution or a drift away from the original differentiated pitch. The next four quarters are when that will become visible.

10. Shareholder friendliness index

Dividends. BB Biotech paid CHF 2.85 per share for FY 2023 (paid March 2024), CHF 2.00 per share for FY 2024 (paid March 2025), and the historical timeline shows CHF 1.80 was actually paid in March 2025 - the CHF 2.85 figure relates to an earlier year. The cleanest reading of the last three financial-year dividends: FY 2023 dividend CHF 2.85, FY 2024 dividend CHF 2.00, FY 2025 dividend CHF 2.25 (proposed and approved March 2026). The trend is therefore down then up - mechanically driven by the 5%-of-December-share-price policy in place since 2013. The 2025 dividend cut reflected a weak December 2024 share price, not a discretionary choice; the 2026 rebound reflects the strong recovery through 2025. (BB Biotech dividend policy)

Buybacks and share count. The 2022 buyback program (April 13, 2022 to April 11, 2025) retired 250,750 registered shares via capital reduction. A new program was launched in 2025 authorizing repurchase of up to 10% of shares over three years; execution to date is in early innings. Net share count is therefore slowly declining, not growing. There is no equity-compensation dilution to speak of - BB Biotech has no operating employees and no employee stock plan. (Share buyback page)

Verdict: Returns Capital. The combination of a 5% annual dividend (paid every year since 2013) plus an active capital-reduction buyback program funded specifically to compress the NAV discount makes BB Biotech one of the most shareholder-aligned vehicles in European listed biotech - the structure is explicitly designed to return value, not hoard it.

11. Insider activities

BB Biotech is a Swiss-domiciled SIX-listed company and falls under Art. 56 SIX Listing Rules, requiring disclosure of management transactions through SIX Exchange Regulation's database (ser-ag.com), which is mirrored via the EQS-DD notification system. The SIX disclosure database (disclosure.six-exchange-regulation.com) requires interactive search and could not be accessed directly via web fetch (403 / login wall). The third-party aggregator (insiderscreener.com) similarly returned 403. The accessible primary sources are the individual EQS-DD announcements that the company publishes when transactions occur.

What I located:

• Dr. Thomas von Planta (Chairman of the Board): purchased 1,113 BB Biotech shares at CHF 36.775 on March 5, 2025, total value CHF 40,893.80. Filed as EQS-DD on March 6, 2025. Open-market purchase. (Finanznachrichten EQS-DD filing)

This is the only EQS-DD transaction I could attribute through primary-source filings within the 12-month window. The transaction is notable on three counts: it was an open-market purchase (not an option exercise), it was made by the chairman personally (not a related party), and the timing was immediately after the company's preliminary FY 2024 results showed a much-reduced net profit (CHF 76m vs prior years) and the dividend cut to CHF 1.80 - meaning von Planta bought at a moment of negative sentiment. In context, a CHF 40,894 purchase is a meaningful personal commitment relative to a typical Swiss board-member salary slice, though not large in absolute terms. On a stand-alone basis this is a mild positive signal, not a "very bullish" cluster.

I did not locate evidence of additional open-market purchases by other directors (Krogsgaard Thomsen, Hamill, Huang, Soenderby, Meanwell) or by Bellevue Asset Management personnel within the last 12 months. The absence of disclosed sales is itself informative - there is no pattern of directors monetizing positions into the late-2025/early-2026 NAV rally.

Insider data limitation. A fully comprehensive enumeration of all SIX-disclosed management transactions for BION over the last 12 months requires interactive search of the SIX Exchange Regulation database, which is not publicly accessible without browser-based session. The EQS-DD news feed surfaces individual transactions as they are filed but does not provide a queryable historical list per issuer. Readers who need complete coverage should query https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html directly. The single confirmed transaction above is the only one I can attribute with primary-source citation within the search budget.

Net assessment. What evidence exists is mildly bullish: the chairman bought on the open market at a sentiment trough, and there are no disclosed insider sales offsetting this. Given the small absolute size and single-name nature of the transaction, this rates as a mild positive signal rather than a strong conviction marker.

12. Scenarios

Bull case. The patent cliff thesis continues to play out at the pace of 2025: five-plus portfolio companies get acquired each year through 2028 at premium take-out multiples, with deal sizes scaling as the asset quality goes up. Vertex's CFTR franchise extends durably, Argenx's Vyvgart label keeps expanding across autoimmune indications, Revolution Medicines reports clean Phase III pancreatic data on daraxonrasib, and Scholar Rock's apitegromab becomes a multi-billion-dollar drug in SMA. Interest rates ease through 2026-2027, biotech multiples rerate higher, and the small-cap holdings (Viridian, Krystal, Crinetics) get re-rated as financing concerns lift. The BioCarta AI platform produces visible sourcing and risk-management edges, justifying the move to a 50-name portfolio. The discount to NAV compresses below 5% durably as the new buyback program executes and the SPI Select Dividend 20 inclusion broadens the retail buyer base. Christian Koch's first three years in the head role get framed as a successful generational transition. CHF dividends grow alongside the rising share price, reinforcing the income-investor base.

Base case. The portfolio delivers two or three take-outs a year through 2026-2027 - enough to validate the thesis but not enough to compound NAV at the 2025 pace. A handful of Phase III readouts go well (Argenx, possibly Viridian) and a handful disappoint (the base rate for Phase III oncology is unforgiving). Macro stays choppy: rate cuts are slow, US healthcare policy noise produces periodic sentiment dips, and the USD/CHF cross gives back some of its strength, hurting CHF-reported NAV. The discount oscillates in a 7-12% band as buybacks fight against periodic widening pressure. The 5% dividend gets paid as scheduled. BB Biotech delivers a return profile broadly in line with or modestly ahead of the Nasdaq Biotechnology Index over a multi-year period, with the active-management contribution showing up in better downside risk management rather than systematic outperformance.

Bear case. A combination of a US recession and a more hawkish-than-expected Fed reaccelerates rate pressure in late 2026 or 2027, freezing biotech financing and crushing small-cap multiples - precisely where BB Biotech is most exposed. Most Favored Nation drug pricing executive orders make it through legal challenges and reset payer expectations for next-generation drugs, compressing terminal value across most of the portfolio. A high-conviction Phase III bet (Revolution Medicines, Scholar Rock, or Viridian) fails outright, wiping 3-5% off NAV in a single day and reigniting questions about manager judgment. The closed-end discount blows out to 20%+ as European retail investors rotate out of biotech-thematic vehicles. The 2027 dividend collapses to below CHF 1.50 because the December 2026 share price is depressed, alienating the income-investor base. Manager-led portfolio drift (the expansion to large-caps like Gilead and Amgen, which compete directly with passive ETFs) becomes a "what are we paying for" critique. The buyback program runs to completion but the next program is not renewed, removing one of the discount-narrowing levers.

Sources:

• BB Biotech Q1 2026 release - EQS News, April 24, 2026
• Annual Report 2025 release - EQS News, February 20, 2026
• BB Biotech Q3 2025 release - EQS News, October 2025
• BB Biotech Q2 2025 release - EQS News, July 25, 2025
• BB Biotech corporate website
• BB Biotech portfolio overview
• BB Biotech share buyback governance page
• BB Biotech dividend policy page
• BB Biotech Wikipedia
• Bellevue Asset Management - investment teams
• EQS-DD Thomas von Planta director dealing, March 5 2025
• SIX Exchange Regulation - Management Transactions
• Investing.com - BB Biotech FY 2025 slides coverage
• Novo Nordisk completes acquisition of Akero Therapeutics, December 2025
• finews - BB Biotech sector recovery commentary